Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 14, Issue 1, Pages 17-24
Publisher
Informa UK Limited
Online
2017-12-11
DOI
10.1080/17425255.2018.1416095
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review
- (2017) Huan Tao et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis
- (2017) Shao-Nan Yu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems
- (2017) Yi Xiong et al. MEDICAL ONCOLOGY
- Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
- (2017) Cristina Pérez-Ramírez et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
- (2016) K. A. Olaussen et al. ANNALS OF ONCOLOGY
- A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer
- (2016) Su Jin Heo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?
- (2016) Marianna Macerelli et al. CANCER TREATMENT REVIEWS
- Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
- (2016) D.A. Fennell et al. CANCER TREATMENT REVIEWS
- CYC1 Predicts Poor Prognosis in Patients with Breast Cancer
- (2016) Yingyan Han et al. DISEASE MARKERS
- On the pharmacogenetics of non-small cell lung cancer treatment
- (2016) Mariacarmela Santarpia et al. Expert Opinion on Drug Metabolism & Toxicology
- Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer
- (2016) Kinga Malottki et al. LUNG CANCER
- Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine
- (2016) Ji-Ye Yin et al. PHARMACOGENOMICS
- Nucleotide excision repair in humans
- (2015) Graciela Spivak DNA REPAIR
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Transcriptional and post-transcriptional regulation of nucleotide excision repair genes in human cells
- (2015) Hailey B. Lefkofsky et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins
- (2015) Marianne S. Poruchynsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer
- (2015) Caglayan Geredeli et al. TUMOR BIOLOGY
- Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
- (2014) Ivana Sullivan et al. CANCER LETTERS
- The emerging era of pharmacogenomics: current successes, future potential, and challenges
- (2014) J.W. Lee et al. CLINICAL GENETICS
- Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer
- (2014) H. Gao et al. GENETICS AND MOLECULAR RESEARCH
- Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer
- (2014) Hongying Lv et al. MEDICAL ONCOLOGY
- Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients
- (2014) Xin Zhao et al. TUMOR BIOLOGY
- Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
- (2014) Ãngela Roco et al. Frontiers in Genetics
- Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer
- (2014) Maimon C. Rose et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
- (2013) M Tiseo et al. BRITISH JOURNAL OF CANCER
- Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: A pooled analysis based on 39 reports
- (2013) Tong-Peng Xu et al. GENE
- Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2013) Gerold Bepler et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour heterogeneity in the clinic
- (2013) Philippe L. Bedard et al. NATURE
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- (2013) Luc Friboulet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation
- (2013) M. Christmann et al. NUCLEIC ACIDS RESEARCH
- Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients
- (2013) RADOSŁAW MLAK et al. ONCOLOGY REPORTS
- Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer
- (2013) Shao-jun Huang et al. TUMOR BIOLOGY
- The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis
- (2013) Yanlong Yang et al. TUMOR BIOLOGY
- A Better Platinum-Based Anticancer Drug Yet to Come?
- (2012) Ulrike Olszewski et al. Anti-Cancer Agents in Medicinal Chemistry
- Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients
- (2012) Xiaoxia Chen et al. Clinical & Translational Oncology
- Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients
- (2012) Dianke Yu et al. TUMOR BIOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
- (2011) Markus Joerger et al. CANCER
- A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer
- (2011) Jian Cheng et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy
- (2011) Shengxiang Ren et al. LUNG CANCER
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- Association Between Polymorphisms of ERCC1 and XPD and Clinical Response to Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer
- (2010) Fan Li et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Resistance to platinum-based chemotherapy in lung cancer cell lines
- (2010) Jianli Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis
- (2010) Ming Yin et al. LUNG CANCER
- Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
- (2010) Alex Chang LUNG CANCER
- DNA Repair Gene Polymorphisms Predict Favorable Clinical Outcome in Advanced Non–Small-Cell Lung Cancer
- (2009) Aristea Kalikaki et al. Clinical Lung Cancer
- Pharmacogenomics of platinum-based chemotherapy in NSCLC
- (2009) Michelle AT Hildebrandt et al. Expert Opinion on Drug Metabolism & Toxicology
- Excision Repair Cross Complementation Group 1 Polymorphisms Predict Overall Survival after Platinum-Based Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer
- (2009) Katsuhiro Okuda et al. JOURNAL OF SURGICAL RESEARCH
- Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients
- (2009) Tomoyoshi Takenaka et al. LUNG CANCER
- Platinum neurotoxicity pharmacogenetics
- (2009) S. R. McWhinney et al. MOLECULAR CANCER THERAPEUTICS
- Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
- (2008) C. Tibaldi et al. CLINICAL CANCER RESEARCH
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
- Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy
- (2008) Xifeng Wu et al. Pharmacogenetics and Genomics
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now